| Symbol | CMND |
|---|---|
| Name | CLEARMIND MEDICINE INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | Canada |
| Telephone | 972-54-5704749 |
| Fax | — |
| — | |
| Website | https://www.clearmindmedicine.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001892500 |
| Description | Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The companys intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Additional info from NASDAQ: |
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial
Read moreClearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
Read moreClearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
Read moreClearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
Read moreClearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
Read moreClearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
Read moreNew Form EFFECT - Clearmind Medicine Inc. <b>Filed:</b> 2026-06-18 <b>AccNo:</b> 9999999995-26-002060 <b>Size:</b> 1 KB
Read moreHRT FINANCIAL LP 🔴 sold 3.2K shares of Clearmind Medicine Inc. (CMND) at $3.32 Transaction Date: Jun 10, 2026 | Filing ID: 000091
Read moreHRT FINANCIAL LP 🔴 sold 2.1K shares of Clearmind Medicine Inc. (CMND) at $3.36 Transaction Date: Jun 10, 2026 | Filing ID: 000082
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05913752 | A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Su… | Phase1 | Alcohol Use Disorder | Recruiting | 2025-04-30 | 2026-12-31 | ClinicalTrials.gov |
| NCT04839770 | MIECH: The Minimally Invasive Endoscopic Surgery With the Axonpen System for Sp… | Na | Intracerebral Hemorrhage | Completed | 2020-08-07 | 2023-01-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Axonpen system | Other | Approved | Intracerebral Hemorrhage | COMPLETED | NCT04839770 |
| Axonpen system | Other | Approved | Intracerebral Hemorrhage | COMPLETED | NCT04839770 |
| CMND-100 | Other | Phase PHASE1 | Alcohol Use Disorder | RECRUITING | NCT05913752 |
| Axonpen system | DEVICE | Approved | Intracerebral Hemorrhage | COMPLETED | NCT04839770 |
| CMND-100 | DRUG | Phase PHASE1 | Alcohol Use Disorder | RECRUITING | NCT05913752 |